Filing Analysis
Lucid Diagnostics Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The filing includes results of operations and financial condition (Item 2.02).
- Includes a business update via Exhibit 99.1.
Lucid Diagnostics Inc. held its annual meeting of stockholders on June 24, 2026, where shareholders approved the election of three Class B directors and an amendment to increase authorized common stock by 100 million shares.
🚩 Red Flags
- Significant increase in authorized share count (from 300M to 400M) which can lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on June 24, 2026, with 84.7% of outstanding shares represented.
- Three Class B directors (James L. Cox, M.D., John R. Palumbo, and Ronald M. Sparks) were re-elected to the Board.
- Shareholders approved an amendment to increase authorized common stock from 300,000,000 to 400,000,000 shares.
- The appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending Dec 31, 2025, was ratified.
Lucid Diagnostics Inc. reported its financial results for the first fiscal quarter ended March 31, 2026, and provided a concurrent business update.
📋 Key Facts
- The report was filed on May 14, 2026, covering the period ending March 31, 2026.
- The filing includes a press release as Exhibit 99.1 detailing the financial performance.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Lucid Diagnostics Inc. closed a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering resulted in approximately $16.8 million in net proceeds intended for working capital and general corporate purposes.
🚩 Red Flags
- Significant shareholder dilution resulting from the issuance of 18 million new shares.
- The $1.00 price point may represent a discount to the market price depending on the trading history prior to the offering.
📋 Key Facts
- Closed the sale of 18,000,000 shares of common stock on April 24, 2026.
- Offering price was set at $1.00 per share.
- Net proceeds are expected to be approximately $16.8 million after underwriting discounts and expenses.
- Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners.
- The offering was conducted under an existing shelf registration statement on Form S-3 (No. 333-291981).
Lucid Diagnostics Inc. entered into an underwriting agreement for a public offering of 18,000,000 shares of common stock at a price of $1.00 per share. The offering is expected to generate gross proceeds of $18 million before expenses.
🚩 Red Flags
- Significant potential dilution to existing shareholders from the issuance of 18 million new shares.
- The $1.00 offering price suggests the company is operating in a low-share-price environment, which often precedes delisting risks or reverse splits in micro-cap stocks.
📋 Key Facts
- Public offering price set at $1.00 per share.
- Total of 18,000,000 shares of common stock to be sold.
- Gross proceeds of $18,000,000; net proceeds of $0.94 per share after underwriting discounts.
- Underwriters include Canaccord Genuity LLC and BTIG, LLC.
- The offering is expected to close on or about April 24, 2026.
- Offering conducted under an existing shelf registration statement (Form S-3).
Lucid Diagnostics Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The disclosure was made via a press release on March 26, 2026, and furnished under Items 2.02 and 7.01.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2025
- Filing date: March 26, 2026
- Exhibit 99.1 contains the full press release and business update
- The report was signed by Dennis McGrath, Chief Financial Officer
Lucid Diagnostics Inc. issued an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025, and provided a general business update.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The filing includes an announcement of financial results and a business update via press release (Exhibit 99.1).
Lucid Diagnostics Inc. announced the appointment of John R. Palumbo to its Board of Directors as a Class B director. His appointment was designated by holders of the company's 12% Convertible Secured Promissory Notes Due 2029.
🚩 Red Flags
- Board seat granted to debt holders (Convertible Note holders) rather than through standard shareholder voting, indicating potential loss of control or influence by creditors.
- The presence of 12% Convertible Secured Promissory Notes suggests significant existing debt obligations that may impact future equity dilution.
📋 Key Facts
- Effective date of appointment: September 22, 2025.
- John R. Palumbo appointed as a Class B director.
- Appointment was triggered by the rights held by holders of the Company's 12% Convertible Secured Promissory Notes Due 2029.
- The appointment is subject to limitations and policies of the company's nominating and corporate governance committee.
- Mr. Palumbo will receive cash fees and equity awards per existing non-employee director compensation policy.
Lucid Diagnostics Inc. closed a public offering of 28,750,000 shares of common stock at $1.00 per share. The company expects to receive approximately $26.9 million in net proceeds to be used for working capital and general corporate purposes.
🚩 Red Flags
- Significant dilution: Issuance of 28.75 million new shares represents a substantial increase in share count.
- Use of proceeds for 'working capital' often indicates a need to cover operational burn rates rather than specific growth assets.
📋 Key Facts
- Closed sale of 28,750,000 shares of common stock on September 11, 2025.
- Offering price was $1.00 per share.
- Includes 3,750,000 shares from the underwriters' over-allotment option, which was exercised in full.
- Net proceeds expected to be approximately $26.9 million after underwriting discounts and expenses.
- Proceeds are earmarked for working capital and general corporate purposes.
- Underwriters included Canaccord Genuity LLC and BTIG, LLC (joint bookrunners) and Maxim Group LLC (co-manager).
Lucid Diagnostics Inc. entered into an underwriting agreement to conduct a public offering of 25,000,000 shares of common stock at $1.00 per share. The offering aims to raise approximately $25 million in gross proceeds.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of 25 million new shares.
- Pricing at $1.00 per share is often characteristic of micro-cap companies needing urgent liquidity.
📋 Key Facts
- Offering size: 25,000,000 firm shares plus a 30-day option for an additional 3,750,000 shares.
- Public offering price: $1.00 per share.
- Underwriting price (net to company): $0.9425 per share.
- Gross proceeds: $25,000,000 (up to $28,750,000 if option is exercised).
- Underwriters: Canaccord Genuity LLC and BTIG, LLC.
- Expected closing date: On or about September 11, 2025.
- The offering is being conducted under an existing S-3 shelf registration statement (No. 333-268560).
Lucid Diagnostics Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2025.
- Filing date: August 13, 2025.
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Company is classified as an emerging growth company.
Lucid Diagnostics Inc. held its annual meeting of stockholders on June 18, 2025, where shareholders approved the election of two directors and a proposal regarding share issuance for existing convertible notes.
🚩 Red Flags
- The approval of share issuance related to 'Senior Secured Convertible Notes' indicates existing debt obligations that will result in potential dilution for common shareholders.
📋 Key Facts
- Annual Meeting held on June 18, 2025, with approximately 70.9% of shares outstanding represented in person or by proxy.
- Stanley N. Lapidus and Jacque J. Sokolov, M.D. were re-elected to the Board of Directors (Class A).
- Stockholders approved a proposal under Nasdaq Listing Rule 5635 regarding the issuance of common stock related to the November 2024 Senior Secured Convertible Notes.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Lucid Diagnostics Inc. entered into an 'at-the-market' (ATM) sales agreement with Maxim Group LLC to offer and sell up to $25,000,000 of common stock. The proceeds are intended for working capital and general corporate purposes.
🚩 Red Flags
- Potential dilution: The company is authorized to issue up to $25M in new equity, which will dilute existing shareholders.
- Use of proceeds (working capital) often indicates a need for immediate liquidity to fund ongoing operations.
📋 Key Facts
- Entered into a Sales Agreement with Maxim Group LLC on May 30, 2025.
- Maximum offering amount is $25,000,000 of shares.
- The offering is an 'at the market' (ATM) offering under Rule 415.
- Agent commission is set at 3.0% of aggregate gross sales prices.
- Proceeds are earmarked for working capital and general corporate purposes.
Lucid Diagnostics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2025.
- Filing date: May 14, 2025.
- The filing includes an announcement of financial results and a business update under Item 2.02.
- The company is classified as an emerging growth company.
Lucid Diagnostics Inc. has replaced Marcum LLP with CBIZ CPAs P.C. as its independent registered public accounting firm following the acquisition of Marcum's attest business by CBIZ. The change is a direct result of this corporate transaction rather than a disagreement between management and the auditor.
🚩 Red Flags
- Going concern language: The previous auditor (Marcum) issued reports for 2023 and 2024 containing an explanatory paragraph regarding the company's ability to continue as a going concern.
- Auditor change combined with existing going concern uncertainty increases risk profile.
📋 Key Facts
- Marcum LLP resigned as the independent auditor on April 23, 2025.
- CBIZ CPAs P.C. was engaged as the new independent auditor on April 23, 2025.
- The change is due to CBIZ CPAs acquiring the attest business of Marcum LLP.
- Marcum's audit reports for fiscal years ended Dec 31, 2024, and Dec 31, 2023, included an explanatory paragraph regarding the Company's ability to continue as a going concern.
Lucid Diagnostics Inc. closed a public offering of 14,375,000 shares of common stock at $1.20 per share on April 11, 2025. The net proceeds from the sale are expected to be approximately $16.1 million.
🚩 Red Flags
- Significant dilution: Issuance of over 14 million new shares at $1.20 per share.
📋 Key Facts
- Closed sale of 14,375,000 shares of common stock at $1.20 per share on April 11, 2025.
- The offering included the full exercise of underwriters' option for 1,875,000 shares.
- Net proceeds are expected to be approximately $16.1 million after underwriting discounts and expenses.
- Proceeds are earmarked for working capital and general corporate purposes.
- Canaccord Genuity LLC served as sole bookrunner; Maxim Group LLC served as co-manager.
Lucid Diagnostics Inc. entered into an underwriting agreement on April 9, 2025, to conduct a public offering of common stock at $1.20 per share. The offering aims to raise approximately $15.0 million in gross proceeds through the sale of 12.5 million shares.
🚩 Red Flags
- Significant dilution for existing shareholders via the issuance of 12.5M+ new shares
- Low share price ($1.20) indicates micro-cap volatility and potential liquidity/listing concerns
- The company is utilizing an S-3 shelf registration, suggesting a need for immediate capital infusion
📋 Key Facts
- Offering price: $1.20 per share
- Firm Shares: 12,500,000 common stock shares at a net price of $1.1286 per share
- Option Shares: Up to 1,875,000 additional shares available via underwriters' option
- Estimated gross proceeds: ~$15.0 million (up to $17.25 million if option is exercised)
- Underwriters: Canaccord Genuity LLC (Representative), Maxim Group LLC (Co-manager)
- Expected closing date: On or about April 11, 2025
- Registration basis: Existing shelf registration statement on Form S-3 (No. 333-268560)
Lucid Diagnostics Inc. filed an 8-K to announce its fiscal year 2024 financial results and provide a general business update via press release.
📋 Key Facts
- Report date: March 24, 2025
- Filing covers fiscal year ended December 31, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1)
- Company is classified as an emerging growth company
Lucid Diagnostics Inc. closed a public offering of 13,939,331 shares of common stock at $1.10 per share on March 5, 2025. The company expects to net approximately $14.5 million from the sale.
🚩 Red Flags
- Significant dilution: Issuance of nearly 14 million shares at a low price point ($1.10) suggests potential significant dilution for existing shareholders.
- Reliance on equity financing: The use of proceeds for 'working capital' often indicates the company is burning cash and needs immediate liquidity to sustain operations.
📋 Key Facts
- Closed sale of 13,939,331 shares of common stock.
- Offering price: $1.10 per share.
- Estimated net proceeds: Approximately $14.5 million (after fees and expenses).
- Use of proceeds: Working capital and general corporate purposes.
- The offering was made under an existing shelf registration statement on Form S-3 (No. 333-268560) filed Nov 25, 2022.
Lucid Diagnostics Inc. announced a significant equity offering of 13,939,331 common shares at $1.10 per share, intended to raise approximately $15.3 million in gross proceeds. The offering is being conducted via a placement agency agreement with Canaccord Genuity LLC and is expected to close around March 5, 2025.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of nearly 14 million new shares.
- The offering is being conducted via a 'best efforts' basis, which provides no guarantee of full capital raise if demand is insufficient.
📋 Key Facts
- Offering size: 13,939,331 shares of common stock.
- Price per share: $1.10.
- Gross proceeds: Approximately $15.3 million.
- Estimated net proceeds: Approximately $14.5 million after fees and expenses.
- Placement Agent: Canaccord Genuity LLC (7.0% fee on gross proceeds + up to $50,000 in legal expense reimbursement).
- Additional cost: $300,000 fee to a financial advisor.
- Closing date: Expected on or about March 5, 2025.
- Registration method: Existing shelf registration statement on Form S-3 (No. 333-268560).
Lucid Diagnostics Inc. has terminated its current At-The-Market (ATM) prospectus supplement dated December 6, 2022. While the underlying Sales Agreement with Cantor Fitzgerald & Co. remains in effect, no further shares will be sold under this specific supplement until a new one is filed.
🚩 Red Flags
- The termination of an ATM program can sometimes indicate a company's desire to avoid further immediate dilution or a pause in capital raising activities due to market conditions.
📋 Key Facts
- Termination of ATM Prospectus Supplement effective March 4, 2025.
- The original Sales Agreement was entered into with Cantor Fitzgerald & Co. in November 2022.
- Aggregate offering amount under the terminated supplement was up to $6,500,000.
- Total shares sold via this specific ATM program to date: 230,068 shares.
- Total aggregate proceeds raised from this program: $292,790.
Lucid Diagnostics Inc. has officially regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share. This resolves a delisting risk that had been pending since June 2024.
🚩 Red Flags
- Historical history of non-compliance with minimum bid price requirements (June 2024 notification).
📋 Key Facts
- Company regained compliance with Nasdaq Listing Rule 5550(a)(2) as of February 24, 2025.
- Compliance was achieved after the closing bid price remained at or above $1.00 per share from February 7, 2025, to February 21, 2025.
- The company had previously been granted an extension of the compliance period until June 16, 2025.
Lucid Diagnostics Inc. has received an extension from Nasdaq, granting an additional 180 days (until June 16, 2025) to regain compliance with the minimum bid price requirement of $1 per share.
🚩 Red Flags
- Delisting notice: Failure to meet minimum bid price requirement ($1.00/share).
- Repeated non-compliance: The company has already exhausted one 180-day compliance period.
- Potential for extreme volatility or reverse stock split if the $1 threshold is not met by June 2025.
📋 Key Facts
- The Company failed to regain compliance within the initial 180-day period that expired on December 18, 2024.
- Nasdaq has granted an additional 180-day extension until June 16, 2025.
- To regain compliance, the stock must close at $1.00 or higher for at least ten consecutive business days during the extension period.
- The Company's common stock continues to trade uninterrupted on the Nasdaq Capital Market under the symbol 'LUCD'.
Lucid Diagnostics Inc. closed a $21.95 million sale of Senior Secured Convertible Notes on November 22, 2024. The company used a portion of the proceeds to redeem its existing 2023 Convertible Note for approximately $3.6 million.
🚩 Red Flags
- High-interest debt restructuring: The company is replacing one convertible note with another, indicating ongoing need for external financing.
- Asset Encumbrance: A security interest has been granted on 'substantially all' property and assets to the 2024 Note Investors.
- Potential Dilution: The issuance of convertible notes and the requirement to file a resale registration statement within 120 days indicates significant potential dilution for existing shareholders.
📋 Key Facts
- Closed sale of $21.95 million in principal amount of Senior Secured Convertible Notes (the '2024 Convertible Notes') on November 22, 2024.
- Gross proceeds: $21.95 million; Net proceeds after debt repayment: $18.3 million.
- Redeemed the 2023 Convertible Note by paying an Optional Redemption Price of approximately $3.6 million.
- The 2024 Convertible Notes are secured by a security interest in substantially all of the company's property and assets via a Pledge Agreement.
- Company agreed to file a resale registration statement for shares underlying the notes within 120 days per a Registration Rights Agreement.
Lucid Diagnostics Inc. has entered into a Securities Purchase Agreement to issue $21.75 million in Senior Secured Convertible Notes to accredited investors. The primary purpose of this capital raise is to redeem existing 2023 Convertible Notes.
🚩 Red Flags
- High level of debt restructuring: The company is replacing one significant convertible note with another, which may indicate a continuous need for external financing to manage existing obligations.
- Convertible Note Dilution: The issuance of Senior Secured Convertible Notes typically results in significant potential dilution for existing shareholders upon conversion.
📋 Key Facts
- Aggregate sale amount: $21.75 million in Senior Secured Convertible Notes (the '2024 Convertible Notes').
- The proceeds are intended to redeem the company's previously issued March 13, 2023, Senior Convertible Note.
- The redemption notice for the 2023 Note was provided on November 8, 2024.
- The transaction is being conducted via a private placement exempt from registration under Section 4(a)(2) of the Securities Act.
- Proceeds from the new issuance are expected to exceed the amount required for the redemption of the old debt.
Lucid Diagnostics Inc. issued an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024, and provided a general business update via press release.
📋 Key Facts
- Report date: November 13, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Company is classified as an emerging growth company.
Lucid Diagnostics is redeeming its existing 2023 Senior Convertible Note and replacing it with new 2024 Senior Secured Convertible Notes to finance the redemption. The new notes feature a 12.0% interest rate, a $1.00 conversion price, and include a significant acceleration event tied to Medicare coverage for the company's EsoGuard product.
🚩 Red Flags
- High interest rate (12.0%) on new debt suggests high perceived risk by lenders.
- The notes are secured by a lien on all company assets, increasing the seniority of this debt over existing equity/unsecured claims.
- Acceleration clause tied to regulatory outcome (Medicare coverage for EsoGuard) creates significant binary risk for the company's solvency.
- Financial covenant requires maintaining at least $5.0 million in available cash while notes are outstanding.
📋 Key Facts
- Company is exercising its right to redeem the 2023 Convertible Note on November 8, 2024.
- New 2024 Convertible Notes feature a 12.0% annual stated interest rate and a 5-year maturity.
- The contractual conversion price for the new notes is $1.00 per share.
- Interest on the 2024 notes can be paid in cash or at the holder's election in common stock.
- New notes are secured by a lien on all present and future tangible and intangible property/assets of the company.
- A specific acceleration event (default) occurs if the company fails to obtain positive Medicare coverage for its EsoGuard product within 18 months of issuance.
Lucid Diagnostics Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024, and provided a general business update via press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024
- Filing date: August 12, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
Lucid Diagnostics Inc. held its annual meeting of stockholders on July 23, 2024, where shareholders approved the election of three Class C directors and several corporate amendments. The meeting also included ratification of the company's independent auditor and approval for Nasdaq compliance regarding previous preferred stock issuances.
🚩 Red Flags
- The need for shareholder approval to comply with Nasdaq Listing Rule 5635 regarding Series B/B-1 preferred stock indicates potential dilution or regulatory compliance requirements related to previous private placements.
📋 Key Facts
- Annual Meeting held on July 23, 2024; 84.6% of shares outstanding were represented.
- Three Class C directors (Lishan Aklog, M.D., Debra J. White, and Dennis A. Matheis) were re-elected.
- Shareholders approved the issuance of common stock under Series B and Series B-1 Convertible Preferred Stock to comply with Nasdaq Listing Rule 5635.
- Shareholders approved an amendment to increase authorized common stock from 200,000,000 to 300,000,000 shares.
- Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Lucid Diagnostics Inc. received a notice from Nasdaq stating the company's common stock has been below the $1 minimum bid price for 30 consecutive business days as of June 20, 2024. The company has been granted a 180-day period to regain compliance by maintaining a $1 closing price for at least ten consecutive business days.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Stock trading below the $1 threshold, indicating significant downward price pressure.
- Risk of delisting if compliance is not met by December 18, 2024.
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications Department on June 21, 2024.
- Violation of Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price ($1.00).
- The deficiency period began after the stock closed below $1 for 30 consecutive business days through June 20, 2024.
- Compliance period: 180 calendar days, expiring December 18, 2024.
- Requirement to regain compliance: Closing bid price must be at least $1.00 for a minimum of ten consecutive business days.
Lucid Diagnostics Inc. has rescheduled its 2024 Annual Meeting of Stockholders from June 20, 2024, to July 23, 2024. The rescheduling is intended to allow the company to modify the proposals to be voted upon at the meeting.
🚩 Red Flags
- Rescheduling of an annual meeting to 'modify proposals' can sometimes indicate unexpected shareholder activism or internal governance shifts, though not explicitly stated here.
📋 Key Facts
- Original Annual Meeting Date: June 20, 2024
- New Annual Meeting Date: July 23, 2024
- New Record Date for voting eligibility: May 29, 2024
- The company is filing a revised preliminary proxy statement on Schedule 14A concurrently with this 8-K.
- Reason for rescheduling: To modify the proposals to be voted upon.
Lucid Diagnostics Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024, and provided a general business update via press release.
🚩 Red Flags
- No specific red flags identified in the text provided; however, quarterly earnings releases often contain discussions regarding cash burn or liquidity which are not detailed in this cover page.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Company is classified as an 'emerging growth company'.
Lucid Diagnostics Inc. completed a $11.6 million offering of newly designated Series B-1 Convertible Preferred Stock to accredited investors on May 6, 2024. The filing also notes the appointment of Dennis Matheis to the Board of Directors.
🚩 Red Flags
- Convertible Preferred Stock with a conversion price ($0.7228) significantly below typical par values suggests potential dilution risk for common shareholders.
- The inclusion of 'dividend sweeteners' (additional shares if held until 2025/2026) can create further dilutive pressure on existing equity holders.
- Beneficial ownership and primary market limitations are in place, which is standard but indicates the complexity of the capital structure.
📋 Key Facts
- Offered approximately 11,634 shares of Series B-1 Convertible Preferred Stock at $1,000 per share.
- Gross proceeds from the offering total approximately $11.6 million.
- Initial conversion price is set at $0.7228 (based on 5-day trailing average VWAP as of May 1, 2024).
- Series B-1 Preferred Stock is senior to Common Stock and pari passu with existing Series B Preferred Stock.
- Dividends include a 20% increase in common stock shares on May 6, 2025, and another 20% on May 6, 2026, if not converted prior.
- Dennis Matheis appointed as Class A director effective May 6, 2024.
Lucid Diagnostics Inc. issued a press release regarding the publication of positive clinical validation data for its EsoGuard Esophageal DNA Test and EsoCheck Collection Device in a peer-reviewed study sponsored by the National Cancer Institute.
📋 Key Facts
- The announcement concerns a peer-reviewed publication of positive data from a National Cancer Institute-sponsored study.
- The study was a prospective, multicenter clinical validation study.
- The technology evaluated includes the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Lucid Diagnostics completed a Series B Preferred Stock offering and exchange involving accredited investors, resulting in $18.16 million in gross proceeds. The transaction involved the issuance of new Series B shares and the exchange of existing Series A and Series A-1 preferred stock.
🚩 Red Flags
- Significant potential dilution via convertible preferred stock with high dividend multipliers (20% bumps).
- Series B shares are senior to common stock in liquidation and dividends.
- Beneficial ownership limitations (4.99%/9.99%) and Market Limit restrictions suggest complex cap table dynamics often seen in distressed financing.
📋 Key Facts
- Total aggregate gross proceeds: $18.16 million (includes $5.67 million from immediate sale/exchange of Series A-1).
- Issuance of 12,495 shares of newly designated Series B Convertible Preferred Stock at $1,000 per share.
- Exchange of 13,625 shares of Series A and 10,670 shares of Series A-1 for 31,790 shares of Series B Preferred Stock.
- Series B conversion price set at an initial $1.2444 per share.
- Mandatory conversion trigger: VWAP of Common Stock at or above $8.00 on 20 out of 30 consecutive trading days.
- Dividend feature: Holders receive a 20% increase in shares issuable upon conversion on March 13, 2025, and another 20% on March 13, 2026.
Lucid Diagnostics Inc. announced that its parent company, PAVmed Inc., elected to receive $4,675,256 in accrued fees and reimbursements through the issuance of 3,331,771 shares of common stock.
🚩 Red Flags
- Related-party transaction involving the parent company (PAVmed Inc.).
- Significant equity dilution: Issuance of over 3.3 million shares to settle debt/expenses.
- Settlement relates to historical expenses dating back to late 2022, indicating delayed settlement or ongoing dependency on parent for payroll/benefits.
📋 Key Facts
- Parent company PAVmed Inc. elected to settle $4,675,256 in accrued fees/reimbursements via equity.
- The settlement covers expenses from October 1, 2022, through December 31, 2022.
- Total shares issued: 3,331,771 common shares of Lucid Diagnostics Inc.
- The issuance is part of existing Management Services and Payroll/Benefit Expense Reimbursement Agreements (MSA and PBERA).